Please use this identifier to cite or link to this item:
Volltext verfügbar? / Dokumentlieferung
doi:10.22028/D291-37762
Title: | Characterization of PD-1 and PD-L1 Expression in Papillary Renal Cell Carcinoma: Results of a Large Multicenter Study |
Author(s): | Erlmeier, Franziska Steffens, Sandra Stöhr, Christine Herrmann, Edwin Polifka, Iris Agaimy, Abbas Trojan, Lutz Ströbel, Philipp Becker, Frank Wülfing, Christian Barth, Peter Stöckle, Michael Staehler, Michael Stief, Christian Haferkamp, Axel Hohenfellner, Markus Macher-Göppinger, Stephan Wullich, Bernd Noldus, Joachim Brenner, Walburgis Roos, Frederik C. Walter, Bernhard Otto, Wolfgang Burger, Maximilian Schrader, Andres Jan Hartmann, Arndt Ivanyi, Philipp |
Language: | English |
Title: | Clinical Genitourinary Cancer |
Volume: | 19 (2021) |
Issue: | 1 |
Pages: | 53-59.e1 |
Publisher/Platform: | Elsevier |
Year of Publication: | 2020 |
DDC notations: | 610 Medicine and health |
Publikation type: | Journal Article |
Abstract: | Background Programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) play a decisive role as prognostic markers in clear-cell renal cell carcinoma (RCC). To date, the role of PD-1/PD-L1 as a prognostic marker in papillary RCC (pRCC) remains scarce. Patients and Methods Patients’ sample collection was a joint collaboration of the nationwide PANZAR consortium – a multicenter study. Medical history and tumor specimens were collected from 245 and 129 patients with pRCC types 1 and 2, respectively. Expression of PD-1 and PD-L1 was determined by immunohistochemistry in pRCC and tumor-infiltrating mononuclear cells. Results Of 374 pRCC specimens, 204 type 1 and 97 type 2 were evaluable for PD-1 and PD-L1 expression analysis. In total, PD-1 and PD-L1 expression were found in 8 (4.9%) of 162 and 12 (7.2%) of 166 evaluable pRCC type 1 specimens. Comparably, PD-1 and PD-L1 expression were found in 2 (2.4%) of 83 and 5 (6.2%) of 81 evaluable pRCC type 2 specimens. Hardly any clinically relevant associations between PD-1 and PD-L1 positivity and clinicopathologic or clinical courses were observed, neither in pRCC type 1 nor type 2. Conclusion The analysis of a large pRCC cohort from a multicenter consortium revealed no impact of PD-1/PD-L1 expression on prognosis in patients with pRCC with predominantly limited disease status, neither for type 1 nor type 2. However, the impact of PD-1 and PD-L1 in more advanced pRCC disease needs further elucidation. |
DOI of the first publication: | 10.1016/j.clgc.2020.07.002 |
URL of the first publication: | https://www.sciencedirect.com/science/article/abs/pii/S155876732030149X |
Link to this record: | urn:nbn:de:bsz:291--ds-377624 hdl:20.500.11880/34157 http://dx.doi.org/10.22028/D291-37762 |
ISSN: | 1558-7673 |
Date of registration: | 28-Oct-2022 |
Faculty: | M - Medizinische Fakultät |
Department: | M - Urologie und Kinderurologie |
Professorship: | M - Prof. Dr. Michael Stöckle |
Collections: | SciDok - Der Wissenschaftsserver der Universität des Saarlandes |
Files for this record:
There are no files associated with this item.
Items in SciDok are protected by copyright, with all rights reserved, unless otherwise indicated.